Abstract: |
The immune repertoire contains T cells and B cells that can recognize autologous cancer cells. This repertoire is directed against self, and in some cases altered self (mutations). Priming immune responses against self antigens can be difficult. Strategies are presented using altered self to elicit immunity against self in poorly immunogenic tumor models. Mechanisms underlying immunity to self antigens on cancer cells show that the immune system can use diverse strategies for cancer immunity, in both the immunization and the effector phases. CD4+ T cells are typically, but not always, required for immunization. The effector phase of tumor immunity can involve cytotoxic T cells, macrophages with activating Fc receptors, and/or killer domain molecules. This diversity in the effector phase is observed even when immunizing with conserved paralogs. A consequence of tumor immunity is potentially autoimmunity, which may be undesirable. Autoimmunity uses similar mechanisms as tumor immunity, but tumor immunity and autoimmunity can uncouple. These studies open up strategies for active immunization against cancer. |
Keywords: |
controlled study; unclassified drug; genetics; mutation; review; nonhuman; neoplasm; neoplasms; t lymphocyte; mouse; animal; animals; mice; melanoma; biological model; skin neoplasms; neoplasm proteins; animal experiment; animal model; tumor antigen; mice, inbred c57bl; b lymphocyte; c57bl mouse; skin tumor; immunological tolerance; biosynthesis; immunology; immune response; species specificity; antigens, neoplasm; immunogenicity; cancer cell; vaccination; epitope; tumor protein; cytotoxic t lymphocyte; organ specificity; experimental melanoma; melanoma, experimental; autoantigen; autoantigens; tumor immunity; species difference; antibody specificity; fc receptor; effector cell; autoimmunity; dna vaccine; t-lymphocyte subsets; cd4 antigen; macrophage; autoantibody; epitopes, t-lymphocyte; autoantibodies; antibodies, neoplasm; testis; glycoprotein; t lymphocyte subpopulation; antigens, differentiation; differentiation antigen; immunization; self tolerance; cancer antibody; antigens, heterophile; vitiligo; models, immunological; passive immunization; immunization, passive; humans; human; male; priority journal; article; glycoprotein gp 75; heterophile antigen
|